Leerink lowered the firm’s price target on Mirum Pharmaceuticals to $43 from $44 and keeps an Outperform rating on the shares. The firm cites Q4 2023 disclosures.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MIRM:
- Mirum Pharmaceuticals’ Financial Uncertainty: FDA Approval Hurdles for Chenodal’s CTX Treatment
- Mirum Pharmaceuticals price target raised to $58 from $45 at H.C. Wainwright
- Mirum Pharmaceuticals price target raised to $72 from $69 at JMP Securities
- 3 Best Stocks to Buy Now, 3/14/2024, According to Top Analysts
- Mirum Pharmaceuticals’ Livmarli receives FDA approval
